Deletion of p53 in MSCs significantly prolonged mice’s survival beyond discontinuation of therapy (p < 0.003), suggesting that survival of AML cells in response to DS-5272 might depend on p53 levels in MSCs (Fig. 4C). This evidence concerns the gene TP53 and acute myeloid leukemia.